Metabolomics : Official journal of the Metabolomic Society · 2025
Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohorts.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heckscher Simon, Ihlo Nicolas A, Schueler Jan, Kellermeier Fabian, Werner Jens M, Nuebel Barbara, Gross Verena, May Matthias, Wullich Bernd, Kammerl Martin, Gnewuch Carsten, Burkhardt Ralph, Buchholz Björn, Pion Eric, Aung Thiha, Banas Miriam, Schlitt Hans J, Oefner Peter J, Dettmer Katja, Gronwald Wolfram, Behr Merle, Haerteis Silke, Schmidt Katharina M
Аннотация
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder characterized by progressive renal cyst formation, often leading to end-stage kidney disease (ESKD). In contrast to the urinary metabolome in ADPKD, the composition of renal cyst fluid remains largely unexplored.
METHODS: We conducted a comprehensive metabolomic analysis of renal cyst fluid from 26 ADPKD patients (20 on dialysis, six with kidney transplants) using ¹H-NMR spectroscopy and liquid chromatography-mass spectrometry (LC-MS). Cysts were clustered based on metabolite profiles, and differences were analyzed across groups defined by renal function status (dialysis vs. transplant), cyst volume, and cyst fluid sodium concentrations.
RESULTS: Dialysis patients and transplant recipients differed significantly in their renal cyst fluid metabolomes. The former exhibited higher concentrations of myoinositol, creatinine, sucrose, τ-methylhistidine, trigonelline, and sarcosine, while the latter showed increased levels of leucine, isoleucine, valine and alanine. Remarkably, metabolites of the immunosuppressive prodrug mycophenolate mofetil were detected in renal cyst fluids after kidney transplantation. Despite intra- and interindividual variability, cyst fluid from the same patient displayed greater homogeneity. Interestingly, metabolomic profiles were not altered by cyst size.
CONCLUSION: This first systematic metabolomic analysis of renal cyst fluid in advanced ADPKD reveals distinct metabolic signatures linked to renal function status. The data provides novel insights into the pathophysiology of ADPKD and highlight the potentials of renal cyst fluid metabolomics for identifying biomarkers and therapeutic targets.
METHODS: We conducted a comprehensive metabolomic analysis of renal cyst fluid from 26 ADPKD patients (20 on dialysis, six with kidney transplants) using ¹H-NMR spectroscopy and liquid chromatography-mass spectrometry (LC-MS). Cysts were clustered based on metabolite profiles, and differences were analyzed across groups defined by renal function status (dialysis vs. transplant), cyst volume, and cyst fluid sodium concentrations.
RESULTS: Dialysis patients and transplant recipients differed significantly in their renal cyst fluid metabolomes. The former exhibited higher concentrations of myoinositol, creatinine, sucrose, τ-methylhistidine, trigonelline, and sarcosine, while the latter showed increased levels of leucine, isoleucine, valine and alanine. Remarkably, metabolites of the immunosuppressive prodrug mycophenolate mofetil were detected in renal cyst fluids after kidney transplantation. Despite intra- and interindividual variability, cyst fluid from the same patient displayed greater homogeneity. Interestingly, metabolomic profiles were not altered by cyst size.
CONCLUSION: This first systematic metabolomic analysis of renal cyst fluid in advanced ADPKD reveals distinct metabolic signatures linked to renal function status. The data provides novel insights into the pathophysiology of ADPKD and highlight the potentials of renal cyst fluid metabolomics for identifying biomarkers and therapeutic targets.